title: Monoclonal antibodies in oncology therapeutics: present and future indications.
abstract: BACKGROUND
  Over the last decade, the field of oncology has undergone revolutionary changes. One of the major reasons contributing to this change is the improvement in our understanding of the biology of cancer. Recognition of novel targets on the cancer cell has enabled development of tools to attack those targets. Monoclonal antibodies represent such a therapy that has rapidly been adapted in almost all major cancer subtypes.
  
  
  METHODS
  This review intends to give a comprehensive overview of monoclonal antibodies, including mechanism of action, the currently approved agents and future targets. The authors reviewed published data as well as information from the ongoing clinical trials.
  
  
  CONCLUSIONS
  Monoclonal antibodies represent a major new advance in oncology therapy but there remains significant room for improvement.
authors.affiliation: Wayne State University, Barbara Ann Karmanos Cancer Institute, Department of Oncology, Department of Medicine, 4 Hudson Webber Cancer Research Center, 4100 John R, Detroit, MI 48201, USA.
authors.forename: Divaya
authors.initials: D
authors.lastname: Bhutani
authors.forename: Ulka N
authors.initials: UN
authors.lastname: Vaishampayan
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects; D003167:Complement Activation / Q000187:drug effects; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000911:Antibodies, Monoclonal